Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 273x168px
Document › Details

Bayer AG. (5/14/14). "Press Release: Bayer HealthCare to Unveil »CoLaborator« in Berlin [Not intended for U.S. and UK Media]". Berlin & Leverkusen.

Region Region Berlin
  Country Germany
Organisations Organisation Bayer HealthCare, CoLaborator Berlin
  Group Bayer (Group)
  Organisation 2 Calico GmbH
  Today Calico Biolabs Inc.
Products Product BIOTECH
  Product 2 business development (state/region)
Persons Person Busch, Andreas (Bayer 201201–201711 Head Global Drug Discovery at Bayer Healthcare LEFT 11/17)
  Person 2 Paulitschke, Manrico (Provitro GmbH 201210 Managing Director)

Not intended for U.S. and UK Media

Incubator for young entrepreneurs in life sciences sets up creative environment for research and innovation in Berlin / First tenants Calico Biolabs, DexLeChem, and provitro already moved in

Bayer HealthCare (Bayer) has officially inaugurated its second research incubator for young life sciences companies at its Berlin location, dubbed 'CoLaborator'. The opening ceremony took place in the presence of Berlin's Governing Mayor Klaus Wowereit.

The aim of the global CoLaborator concept is to offer young companies in the area of chemistry and biosciences ready-to-use laboratory and office infrastructure in the immediate vicinity of Bayer's own research facilities. In this way, the 'CoLaborator' creates an ideal environment in which to advance research and innovation.

"Berlin is a leading science location. The new CoLaborator shall promote the exchange of knowledge and expertise among top international researchers in the city and help startup companies put their ideas into practice," said Berlin's Governing Mayor Klaus Wowereit. "With globally recognized universities and research institutions, technology parks, the Bayer research center, and an inspiring startup scene, the Berlin region is one of the most important scientific regions in Europe. I am delighted that Berlin will further strengthen and expand this position."

The newly opened 'CoLaborator' in Berlin enables young life sciences companies to rent equipped research laboratories and office space in a separate building with approx. 800 square meters of floor space and about 420 square meters space for laboratories. The 'CoLaborator' can house up to nine small companies. The young firms' fields of activity should correlate with the diversity of Bayer's research interests, so that both young entrepreneurial spirit and pharmaceutical expertise can nourish each other. The new 'CoLaborator' is located at Bayer's R&D Center at Müllerstrasse 178, 13353 Berlin.

"As an innovation-driven company, we want to enable young entrepreneurs to realize their innovative ideas," said Prof. Dr. Andreas Busch, member of the Bayer HealthCare Executive Committee and Head of Global Drug Discovery. "With the CoLaborator we are creating an environment where young companies find ideal conditions for this purpose. In addition, we are encouraging scientific exchange and want to create a stimulating environment for research and innovation. The establishment of the CoLaborator is a logical step in enhancing our partnership models in research and thus an important element of our innovation strategy."

The first tenants, Calico GmbH, DexLeChem GmbH and provitro AG, have already moved into the CoLaborator premises in Berlin.


About the first tenants in the 'CoLaborator'

Calico GmbH is involved in the development of monoclonal antibodies and biomarkers. DexLeChem GmbH engages in research and development in the field of homogeneous chiral catalysis. Provitro AG operates in the fields of tissue microarrays, immunohistochemical analyses and cell-culture technology.

"We are excited about the move of Calico into the CoLaborator in Berlin, where we set up our first location in Europe," says Robert Pytela, CEO of Calico GmbH. "The proximity to the Bayer scientists and other leading researchers in Berlin offers an exciting environment in which we can further develop and apply our technologies."

"The CoLaborator is the ideal environment for DexLeChem to enable us to internationalize our young company and to continuously expand our range of development services in green chemistry," says Sonja Jost, CEO of DexLeChem GmbH. "Here we can grow and simultaneously interact with scientists from Bayer. In this way, we receive assistance in areas that are important for our young company."

"The CoLaborator premises and the close proximity of Charité hospital are an excellent situation for the provitro team," says Dr. Manrico Paulitschke, CEO of provitro AG. "We have been able to expand our know-how in the field of target validation over the past few years. We are looking forward to developing further solutions to questions in the bio-sciences and to the collaboration with Bayer."

About Calico

Calico GmbH offers innovative methods to develop recombinant monoclonal antibodies to engineer both bio-therapeutics as well as bio-marker products. Calico's founding members have previously held key scientific functions in leading companies in the diagnostic immunohistochemistry such as Epitomics, Spring Bioscience, and Ventana, where they have contributed to the development of biomarkers.The employees of Calico offer scientific leadership in all aspects of cell biology, DNA cloning, protein engineering and diagnostic pathology. In 2013, Calico Biolabs, Inc. was founded in San Francisco and is now continuing as Calico GmbH its innovative development in the field of biomarkers at the Bayer HealthCare CoLaborator in Berlin.

About DexLeChem

Founded out of the Cluster of Excellence UniCat (Unifying Concepts in Catalysis) DexLeChem GmbH is changing the chemical-pharmaceutical industry with green high-tech services, creating a new state of the art with its innovations. The company is able to produce active chemical substances in water and other sustainable solvents. These novel, patented synthesis routes are more cost-effective than procedures in toxic organic solvents, since DexLeChem can keep the required and expensive noble-metal catalysts active and re-use them, even in water. The interdisciplinary team currently counts eight employees and specializes in chemical engineering, chiral catalysis and quantum physics. Innovator and co-founder is Sonja Jost, who is also the company's chief executive officer. Since April 2014 the company is located at the Bayer HealthCare CoLaborator, Müllerstrasse 178, 13353 Berlin. More information at

About provitro

Provitro AG is an innovative molecular-pathological service provider for preclinical and clinical research in pharmacology and biotechnology. The company's principal business area is based on a well-stocked tissue bank and close scientific cooperation with Charité University Hospital Berlin. The basis of its second line of business is its proprietary know-how in cell biology; it comprises a broad spectrum of cell-culture products. Furthermore, in 2012, provitro has set up a laboratory for molecular-pathological services in tumor and pathogen diagnostics. The certified company concentrates on the interfaces between research and development, in order to find new approaches for future research projects.

About the Bayer HealthCare CoLaborator concept

The aim of the global incubator concept is to help academic researchers at young life sciences companies to establish their research laboratories. The independent companies can get access to the Bayer expertise and the global research network, in addition to the ready to use laboratory and office infrastructure. Bayer HealthCare's first CoLaborator was established in 2012 at the Mission Bay location, San Francisco, in the immediate vicinity of BHC's own research labs. All CoLaborator tenants have the possibility of working and exchanging ideas and experiences internationally at both CoLaborator locations. Bayer's vision is to serve the young companies as the first point of contact in the search for potential collaboration partners in the pharmaceutical industry.

About Bayer HealthCare

The Bayer Group is a global enterprise with core competencies in the fields of health care, agriculture and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of EUR 18.9 billion (2013), is one of the world's leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare's aim is to discover, develop, manufacture and market products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 56,000 employees (Dec 31, 2013) and is represented in more than 100 countries. More information is available at

Our online press service is just a click away:

Follow us on facebook:
Follow us on Twitter:

Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Record changed: 2017-04-02


Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 273x168px

More documents for Bayer (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [LSUS] – The Business Web Portal 600x60px

» top